Literature DB >> 25634514

High GOLPH3 expression is associated with poor prognosis and invasion of hepatocellular carcinoma.

Qian Li1, Yuwen Ma1, Wanpeng Xu2.   

Abstract

Golgi phosphoprotein 3 (GOLPH3) overexpression has previously been associated with the progression of several solid tumors, which resulted in adverse clinical outcomes. The present study aimed to determine the expression and prognostic significance of GOLPH3 in human hepatocellular carcinoma (HCC). GOLPH3 expression was examined using western blot analysis of 30 paired samples of HCC and adjacent non‑cancerous liver tissues. GOLPH3 expression levels were also assessed using immunohistochemistry in 180 HCC samples and paired controls. In addition, the association of GOLPH3 expression with clinicopathological features and clinical outcome was analyzed. Furthermore, the effect of GOLPH3 on HCC cell proliferation and invasion were determined. Western blot analysis revealed that GOLPH3 expression was significantly elevated in HCC tissue compared with that of the matched adjacent non‑cancerous liver tissue. In addition, the results of the immunohistochemical analysis demonstrated that GOLPH3 expression was positively correlated with the Edmondson‑Steiner grade (P=0.006), vascular invasion (P=0.002) and serum α feto‑protein levels (P=0.015). GOLPH3 expression was found to be an independent factor for predicting the poor overall survival of HCC patients (hazard ratio, 2.01; 95% confidence interval, 1.26‑3.64; P=0.025). In addition, GOLPH3 silencing inhibited the proliferation, invasion and migration of HCC cell lines in vitro. In conclusion, the results of the present study demonstrated that high GOLPH3 levels may be a potential biomarker for the poor prognosis of patients with HCC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25634514     DOI: 10.3892/mmr.2015.3267

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  6 in total

Review 1.  A meta-analysis of the prognostic significance of Golgi protein 73 in hepatocellular carcinoma in Chinese patients.

Authors:  Jian Zhang; Manka Zhang; Huimin Ma; Xincheng Song; Lingling He; Xiaohui Ye; Xin Li
Journal:  Arch Med Sci       Date:  2019-03-25       Impact factor: 3.318

2.  GOLPH3: a novel biomarker that correlates with poor survival and resistance to chemotherapy in breast cancer.

Authors:  Shicong Tang; Hong Pan; Wei Wei; Huawei Yang; Jianlun Liu; Rirong Yang
Journal:  Oncotarget       Date:  2017-10-19

3.  The knocking down of the oncoprotein Golgi phosphoprotein 3 in T98G cells of glioblastoma multiforme disrupts cell migration by affecting focal adhesion dynamics in a focal adhesion kinase-dependent manner.

Authors:  Cecilia Arriagada; Charlotte Luchsinger; Alexis E González; Tomás Schwenke; Gloria Arriagada; Hugo Folch; Pamela Ehrenfeld; Patricia V Burgos; Gonzalo A Mardones
Journal:  PLoS One       Date:  2019-02-19       Impact factor: 3.240

4.  MiR-3150b inhibits hepatocellular carcinoma cell proliferation, migration and invasion by targeting GOLPH3.

Authors:  Yi Zhang; Jianjun Wang; Hongling Su
Journal:  J Investig Med       Date:  2019-12-05       Impact factor: 2.895

5.  Golgi phosphoprotein 3 (GOLPH3) promotes endometrial carcinoma cell invasion and migration by regulating the epithelial-mesenchymal transition.

Authors:  Yu Wen; Xiaoqing Tan; Xia Wu; Qin Wu; Yan Qin; Miao Liang; Guangqin Ran; Huiying Gu; Rongkai Xie
Journal:  Cancer Biomark       Date:  2019       Impact factor: 4.388

6.  TMEM165, a Golgi transmembrane protein, is a novel marker for hepatocellular carcinoma and its depletion impairs invasion activity.

Authors:  Jee-San Lee; Mi-Yeun Kim; Eun-Ran Park; Yan Nan Shen; Ju-Yeon Jeon; Eung-Ho Cho; Sun-Hoo Park; Chul Ju Han; Dong Wook Choi; Ja June Jang; Kyung-Suk Suh; Jungil Hong; Sang Bum Kim; Kee-Ho Lee
Journal:  Oncol Rep       Date:  2018-07-12       Impact factor: 3.906

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.